What’s new

• FY26 profit of ₹7.69 lakh compares to a ₹102.73 lakh loss in FY25.
• Annual revenue reached ₹27.43 crore, a 7.9% increase.
• The board re-appointed directors and auditors in a routine annual meeting.

Why it matters

The company has moved out of the red, but the absolute scale of earnings remains negligible for a listed entity. With no new guidance or major contracts announced, this is a procedural disclosure.

What we’re watching

• Whether the company can maintain positive margins in FY27.
• Any potential for business expansion beyond current run rates.
• Liquidity levels for such a small-cap stock.

The full read

Link Pharma Chem is back in the black. It reported a net profit of ₹7.69 lakh for FY26, a sharp reversal from the ₹102.73 lakh loss seen in FY25.

Revenue for the year climbed 7.9% to ₹27.43 crore. Given the firm's miniscule market capitalization of just ₹13 crore, these figures reflect minor operational shifts rather than any tectonic change in the business model. The board used its meeting to handle standard governance chores, including re-appointing auditors and directors. There is absolutely nothing in this disclosure that suggests a departure from the performance trends already visible in prior quarterly filings. The company remains a nano-cap player with limited scale, and this routine annual report provides no new catalysts for investors to consider.

Primary source: BSE · NSE

What’s new

• Link Pharma Chem reported a net profit of ₹7.69 lakhs for FY26.
• The company recorded a loss of ₹102.73 lakhs in the previous fiscal year.
• A Q4 loss of ₹40.86 lakhs offset the total annual gains.

Why it matters

Turning a profit is a hurdle for any company, but this nano-cap remains thinly traded with a market value of just ₹13 crore. The reversal to profit is a shift, but the Q4 loss suggests the business model has not found a stable earnings base.

What we’re watching

• Whether the company can post consecutive profitable quarters.
• Any shift in the company's trading volumes.
• Whether directors re-appointed in this filing signal a change in direction.

The full read

Link Pharma Chem closed FY26 with a net profit of ₹7.69 lakhs, a pivot from the ₹102.73 lakhs loss reported in FY25. For a company with a market cap of only ₹13 crore, the shift moves the needle on the balance sheet but does little to alter the company's standing as a nano-cap. The annual figure masks volatility within the year, specifically a ₹40.86 lakh loss in the final quarter. Beyond the bottom line, the filing contains nothing that changes the outlook for the business. The re-appointment of two directors is a routine governance procedure. Investors should view these numbers as a simple accounting reality rather than a sign of operational expansion. The next test is whether the company can sustain its momentum or if it will return to the losses seen in previous cycles.

Primary source: BSE · NSE